Objectives: The aim of the AIDA STEMI (Abciximab iv Versus ic in ST-elevation Myocardial
Infarction) cardiac magnetic resonance (CMR) substudy was to investigate potential benefits …

Background Intracoronary (IC) administration of glycoprotein IIb/IIIa inhibitors (GPIs) has
been studied as an adjunctive therapy to improve outcomes in patients with ST-segment …

Objectives: To perform a systematic up-to-date review and critical discussion of potential
clinical applications of cangrelor based on its pharmacologic properties and the main …

Introduction Large thrombus burden in patients with ST elevation myocardial infarction
(STEMI) is associated with higher rates of distal embolization, no-reflow phenomenon …

Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute
myocardial infarction after ou Page 1 Address for correspondence: Julia M. Umińska, MD …

Acute ST-segment elevation myocardial infarction (STEMI) is a dynamic, thrombus-driven
event. As understanding of its pathophysiology has improved, the central role of platelets in …

Background: The aim of the study was to assess the antiplatelet effect of ticagrelor in
patients with myocardial infarction (MI) after out-of-hospital cardiac arrest (OHCA) treated …

Soon after identification of the platelet membrane glycoprotein (GP) IIb/IIIa, it has become a
target of antiplatelet therapy. There are 3 intravenous GP IIb/IIIa receptor inhibitors, namely …

Therapeutic monoclonal antibodies (mAbs) are the fastest growing area of drug
development, with an increasing number of diseases, including rheumatoid arthritis, multiple …

Background and aim: This systematic review with meta-analysis sought to compare the
efficacy and safety of intracoronary (IC) vs. intravenous (IV) administration of glycoprotein …